Zhang Linfan, Feizi Nikta, Chi Chen, Hu Pingzhao
Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB, Canada.
Centre for Healthcare Innovation, Winnipeg Regional Health Authority and University of Manitoba, Winnipeg, MB, Canada.
Front Genet. 2018 Oct 1;9:421. doi: 10.3389/fgene.2018.00421. eCollection 2018.
The increasing prevalence of diagnosed breast cancer cases emphasizes the urgent demand for developing new prognostic breast cancer biomarkers. Copy number alteration (CNA) burden measured as the percentage of the genome affected by CNAs has emerged as a potential candidate to this aim. Using somatic CNA data obtained from METABRIC (Molecular Taxonomy of Breast Cancer International Consortium), we implemented Kaplan-Meier estimators and Cox proportional hazards models to examine the association of CNA burden with patient's overall survival (OS) and disease specific survival (DSS). We also evaluated the association by considering patients' age and tumor subtypes using stratified Cox models. We delineated the distribution of CNA burden in sample genomes and highlighted chromosomes 1, 8, and 16 as the carriers of the highest CNA burden. We identified a strong association between CNA burden and age as well as CNA burden and breast cancer PAM50 subtypes. We found that controlling the effects of both age (bound by 45-year) and PAM50 subtypes on patient survival using stratified Cox models, would still result in significant association between CNA burden and patients overall survival in both Discovery and Validation data. The same trend was observed in disease specific survival when only PAM50 subtypes were controlled in the stratified Cox models. Our analysis showed that there is a significant association between CNA burden and breast cancer survival. This result is also validated by using TCGA (The Cancer Genome Atlas) data. CNA burden of breast cancer patients has a considerable potential to be used as a novel prognostic biomarker.
确诊乳腺癌病例的日益增多凸显了开发新的乳腺癌预后生物标志物的迫切需求。以受拷贝数改变(CNA)影响的基因组百分比衡量的CNA负担已成为实现这一目标的潜在候选指标。利用从METABRIC(国际乳腺癌分子分类联盟)获得的体细胞CNA数据,我们实施了Kaplan-Meier估计器和Cox比例风险模型,以检验CNA负担与患者总生存期(OS)和疾病特异性生存期(DSS)之间的关联。我们还使用分层Cox模型,通过考虑患者年龄和肿瘤亚型来评估这种关联。我们描绘了样本基因组中CNA负担的分布,并突出显示1号、8号和16号染色体是CNA负担最高的载体。我们发现CNA负担与年龄以及CNA负担与乳腺癌PAM50亚型之间存在密切关联。我们发现,在发现数据和验证数据中,使用分层Cox模型控制年龄(以45岁为界)和PAM50亚型对患者生存的影响,CNA负担与患者总生存期之间仍会存在显著关联。当在分层Cox模型中仅控制PAM50亚型时,疾病特异性生存期也观察到相同趋势。我们的分析表明,CNA负担与乳腺癌生存之间存在显著关联。使用TCGA(癌症基因组图谱)数据也验证了这一结果。乳腺癌患者的CNA负担具有作为一种新型预后生物标志物的巨大潜力。